Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis

Lancet Infect Dis. 2024 Oct;24(10):1069-1071. doi: 10.1016/S1473-3099(24)00294-9. Epub 2024 Jun 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antitubercular Agents* / therapeutic use
  • Drug Resistance, Bacterial
  • Drug Therapy, Combination
  • Humans
  • Mycobacterium tuberculosis / drug effects
  • Rifampin* / therapeutic use
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Rifampin
  • Antitubercular Agents